[{"orgOrder":0,"company":"Getz Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"PAKISTAN","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"||Insulin receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Heart Health Research Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Heart Health Research Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Heart Health Research Center \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Heart Health Research Center \/ AstraZeneca"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Copper","moa":"||Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Copper","moa":"||Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"American Regent \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 10, 2023

                          Lead Product(s) : Tralement,Zinc,Copper,Selenious Acid

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 22, 2022

                          Lead Product(s) : Tralement,Zinc,Copper,Selenious Acid

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Heart Health Research Center

                          Country arrow
                          EPSC
                          Not Confirmed

                          Heart Health Research Center

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          February 14, 2022

                          Lead Product(s) : Xuezhikang,Inapplicable

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Getz Pharma

                          Country arrow
                          EPSC
                          Not Confirmed

                          Getz Pharma

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          December 17, 2021

                          Lead Product(s) : Insulin,Inapplicable

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Gabrail Cancer Center Research

                          Country arrow
                          EPSC
                          Not Confirmed

                          Gabrail Cancer Center Research

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Orlistat,Inapplicable

                          Therapeutic Area : Pharmacology/Toxicology

                          Study Phase : Phase IV

                          Sponsor : Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 11, 2018

                          Lead Product(s) : Orlistat,Inapplicable

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Medical Corps, Israel Defense Force

                          Country arrow
                          EPSC
                          Not Confirmed

                          Medical Corps, Israel Defense Force

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 01, 2017

                          Lead Product(s) : Scopolamine,Meclizine Hydrochloride

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          University of Florence

                          Country arrow
                          EPSC
                          Not Confirmed

                          University of Florence

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 04, 2016

                          Lead Product(s) : Sugammadex Sodium,Rocuronium Bromide,Fentanyl,Propofol,Sevoflurane

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Federal University of Minas Gerais

                          Country arrow
                          EPSC
                          Not Confirmed

                          Federal University of Minas Gerais

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 16, 2015

                          Lead Product(s) : Propofol,Desflurane

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Baxter Healthcare Corporation | Medtronic plc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 12, 2012

                          Lead Product(s) : Fluvastatin Sodium,Inapplicable

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank